These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 601838)

  • 1. Initial clinical experience with the radiosensitizing nitroimidazole Ro 07-0582.
    Jentzsch K; Kärcher KH; Kogelnik HD; Maida E; Mamoli B; Wessely P; Zaunbauer F; Nitsche V
    Strahlentherapie; 1977 Dec; 153(12):825-31. PubMed ID: 601838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
    Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
    Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small prospective study of chordomas treated with radiotherapy and razoxane.
    Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
    Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study.
    Menei P; Venier MC; Gamelin E; Saint-André JP; Hayek G; Jadaud E; Fournier D; Mercier P; Guy G; Benoit JP
    Cancer; 1999 Jul; 86(2):325-30. PubMed ID: 10421269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells.
    Moore BA; Palcic B; Skarsgard LD
    Radiat Res; 1976 Sep; 67(3):459-73. PubMed ID: 959489
    [No Abstract]   [Full Text] [Related]  

  • 8. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization by tinidazole: pharmacokinetic study.
    Cossu F; Rombi GP; Mazza S; Facchini A
    Int J Clin Pharmacol Res; 1986; 6(4):317-23. PubMed ID: 3759284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience.
    Huilgol NG; Dobrowsky W; Tatsuzaki H; Chatterjee NA; Kagiya VT; Das K
    Indian J Cancer; 2002 Jun; 39(2):39-44. PubMed ID: 12789723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.
    Urtasun RC; Band P; Chapman JD; Rabin HR; Wilson AF; Fryer CG
    Radiology; 1977 Mar; 122(3):801-4. PubMed ID: 841074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
    Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
    Palcic B; Faddegon B; Skarsgard LD
    Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
    Ono K; Takahashi M; Nishidai T; Dodo Y; Shibamoto Y; Hiraoka M; Yukawa Y; Abe M
    Radiat Med; 1984; 2(1):71-5. PubMed ID: 6242712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
    Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
    Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer.
    Mattson K; Holsti LR; Niiranen A; Kivisaari L; Iivanainen M; Sovijärvi A; Cantell K
    J Biol Response Mod; 1985 Feb; 4(1):8-17. PubMed ID: 2984340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of Ro 03-8799: racemic mixture and enantiomers.
    Newman HF; Dunphy EP; Bleehen NM; Dische S; Saunders MI; Des Rochers C; Workman P; Lenox-Smith I; Smithen CE
    Br J Radiol; 1986 Oct; 59(706):997-9. PubMed ID: 3768642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF; Bleehen NM; Workman P
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.